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Abstract
In contrast to the well-characterized T cell receptor (TCR) signaling pathways that induce genes that drive T cell
development or polarization of naı ¨ve CD4 T cells into the diverse TH1, TH2, TH17 and Treg lineages, it is unclear what signals
maintain specific gene expression in mature resting T cells. Resting T cells residing in peripheral lymphoid organs exhibit
low-level constitutive signaling. Whereas tonic signals in B cells are known to be critical for survival, the roles of tonic signals
in peripheral T cells are unknown. Here we demonstrate that constitutive signals in Jurkat T cell lines are transduced via the
adapter molecule LAT and the Ras exchange factor RasGRP1 to maintain expression of TCRa mRNA and surface expression
of the TCR/CD3 complex. Independent approaches of reducing basal activity through the LAT-diacylglycerol-RasGRP
pathway led to reduced constitutive Ras-MEK-ERK signals and decreased TCRa mRNA and surface TCR expression in Jurkat
cells. However, loss of TCR expression takes several days in these cell line experiments. In agreement with these in vitro
approaches, inducible deletion of Lat in vivo results in reduced TCRa mRNA- and surface TCR- expression in a delayed
temporal manner as well. Lastly, we demonstrate that loss of basal LAT-RasGRP signals appears to lead to silencing or
repression of TCRa transcription. We postulate that basal LAT-diacylglycerol-RasGRP signals fulfill a regulatory function in
peripheral T lymphocytes by maintaining proper gene expression programs.
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Introduction
The adaptor molecule LAT plays a crucial role in conducting
intracellular signals following engagement of the T cell receptor
(TCR) on thymocytes or peripheral T cells [1]. Phosphorylation of
several conserved tyrosines in LAT provides a platform of binding
sites for the SH2 domains of many other signaling molecules that
connect receptor-proximal signals to downstream calcium and
MAP kinase pathways [2]. Tyrosine-phosphorylated LAT recruits
SLP-76 together with the Tec family kinase Itk, as well as
phospholipase C c1 (PLCc1). Itk-mediated phosphorylation of
phospholipase Cc1 (PLCc1) leads to its activation and to the
generation of IP3 (inositol 1,4,5-trisphosphate) and DAG (diacyl-
glycerol). IP3 binding to its receptors on the endoplasmic
reticulum triggers the calcium pathway [3]. DAG can recruit
PKC (protein kinase C) family members and RasGRPs (Ras
guanyl nucleotide releasing protein) to the membrane [4] to
increase RasGTP, which couples to the RAF-MEK-ERK kinase
cascade to induce changes in gene expression. This includes
increases in transcripts of TCRa and TCRb [5] and the activation
marker CD69 [6]. These DAG-induced transcriptional events can
be mimicked by treatment of cells with the synthetic DAG-analog
PMA (phorbol 12-myristate 13-acetate). In addition to gene
expression, these receptor-induced signals regulate the actin
cytoskeleton [1]. For instance, SLP-76 can recruit the adapter
Nck and the Rho/Rac GEF (guanine nucleotide exchange factor)
Vav, which, together with other molecules, orchestrate cytoskeletal
changes [2].
Both B- and T-lymphocytes also exhibit evidence of tonic
antigen receptor signaling in the resting state, i.e. when antigen
receptors are not ‘‘actively’’ triggered by their cognate antigens
[7]. Freshly isolated thymocytes or peripheral T cells from lymph
nodes demonstrate basal levels of TCRf phosphorylation [8] and
association of ZAP-70 with phospho-TCRf [9,10]. The precise
origin and function of the signal(s) responsive to these receptor-
proximal events is an area of debate. The role of tonic signaling in
B lymphocytes has been more clearly delineated. B cells critically
rely on expression of surface IgM for their survival [11]. The tonic
signal has been suggested to result from BCR self-aggregation,
raft-localization, and/or balances between BCR-associated kinases
and phosphatases [7], and is, in part, mediated through a non-
classical NFkB [12] and/or a PI3 kinase [13] pathway. The
consequences of tonic TCR signals in naı ¨ve T cells is more
controversial. Currently three non-exclusive roles have been
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[14]. Interestingly, inducible deletion of TCRa results in much
more modest reduction in naı ¨ve CD4 T cell numbers (,40%
reduction in half-life) [15] compared to IgM removal from B cells
[11]. The second and third models propose that tonic TCR
signaling has an immuno-modulatory function, either enhancing
[10] or blunting [16,17] TCR responses to antigen.
In contrast to the biochemical signaling events and transcrip-
tional responses that are known to occur when the TCR is fully
stimulated by peptide-MHC [1], much less is known about the
molecular and biochemical details of tonic signaling in T cells. We
have previously demonstrated that tonic signals in cell lines and in
ex vivo thymocytes repress the expression of a cluster of genes [18].
This cluster contains the RAG genes, just as in B cells [19,20]. We
characterized some of the responsible biochemical mechanisms
and demonstrated that tonic ERK and Abl kinase activities
depend on the adapter LAT to synergistically repress RAG gene
expression [18]. Here we describe how tonic signals can also
function in a reciprocal manner; that is, to maintain gene
expression. We find that basal LAT-DAG-RasGRP1 dependent
signals are critical to maintain normal expression levels of TCRa
transcripts.
Results
Independent mutant Jurkat T cell lines with a defective
basal Ras signaling pathway
We previously identified a mutant clone, JPRM441, via a screen
for mutant Jurkat T cell lines with defects in PMA-induced Ras
activation and consequent CD69 upregulation (Figure S1A–C).
We previously reported the signaling defects resulting from
JPRM441’s 90% reduction in RasGRP1 expression [21]. The
same screen yielded additional clones. Complementation assays
(Figure S1D) indicated that clones JPRM441, 471, 477, 563, and
671 are all unique. In contrast to JPRM441, these other 4 lines
express normal levels of RasGRP1, -2, and -3 mRNA (Figure 1A) as
well as normal levels of RasGRP1 and PKCh protein [21]. In
addition to PMA-induced Ras activation, we analyzed basal
activation of Ras as well as phosphorylation of ERK kinases that
lie downstream of active Ras (RasGTP). These constitutive Ras-
ERK signals were reduced in JPRM441, 471, 477, and 671 cells,
comparable to the decreased basal signal we had previously
reported for LAT-deficient J.CaM2 cells [18] (Figure 1B). In
contrast, constitutive Ras-ERK signals were readily detectable in
wild type Jurkat T cells and the JPRM563 line (Figure 1B and data
not shown). The defects responsible for the impaired PMA-
induced, or tonic, Ras signaling pathway in the JPRM471, 477,
563, and 671 lines are unknown. JPRM563 is unique in that
transient expression of Ras with an activating mutation (H-
RasG12V) does not induce CD69 upregulation (Figure S1E),
demonstrating that a defect in JPRM563’s pathway leading to
CD69 lies downstream of Ras. All other lines, including
JPRM441, demonstrated effective induction of CD69 expression
driven by H-RasG12V, indicating that this oncogenic Ras allele
can signal to the downstream RAF-MEK-ERK kinase cascade in
these JPRM lines (Figure S1E).
We next analyzed Ras-ERK signaling in the basal state using
the RasGRP1-deficient JPRM441 and LAT-deficient J.CaM2
cells, as well as lines stably reconstituted with RasGRP1 or LAT.
Analysis of ERK phosphorylation revealed that this signal relies on
the presence of LAT and RasGRP1 and that impaired tonic ERK
phosphorylation was partially rescued in the wild type cDNA-
reconstituted lines (Figure 1C).
Loss of TCR/CD3 expression on mutant Jurkat T cell lines
correlates with reduced tonic Ras-ERK signaling
A survey of surface CD3 expression on resting JPRM441 and
other JPRM mutant lines revealed a surprising phenomenon: the
observed defects in signaling proximal of Ras, but not distal of Ras,
correlated with the loss of surface expression of the TCR/CD3
complex (Figure 2A). As we previously reported [18], LAT-
deficient Jurkat cells (J.CaM2) [22] exhibited reduced TCR and
CD3 surface expression (Figure 2A), as did some other clones
generated by this J.CaM mutagenesis screen for Jurkat clones with
defective TCR-induced calcium mobilization [23,24]. A third
screen for mutant Jurkat lines with defective TCR-induced CD69
upregulation utilizing retroviral insertion as a means of gene
disruption also resulted in a subpopulation of CD3 negative cells
[25]. Thus, loss of normal TCR/CD3 surface expression appears
to be a common finding in these three screens designed to identify
Jurkat T cell lines defective for intracellular signaling proteins.
To test if loss of LAT or RasGRP1 expression was responsible
for loss of TCR/CD3 expression we examined stable reconstituted
cell lines. Stable reconstitution of J.CaM2 cells with wild type LAT
resulted in a relatively efficient restoration of CD3 surface
expression (Figure 2B). In contrast, reconstitution of RasGRP1
expression did not have the same effect on CD3 expression in
JPRM441 (Figure 2B). Additional JPRM441 clones with reconsti-
tuted RasGRP1 expression demonstrated the same resistance to
reconstitution of CD3 expression (not shown). Analyses of
expression of several other cell surface markers revealed that
reconstitution of LAT or RasGRP1 resulted in a restoration of
expression of some (e.g. CD38) but not of other (e.g. CD62L and
CD2) cell surface markers (Figure S2). Given the recurrent
correlation between lack of signaling molecules and TCR/CD3
expression in cell lines, we next focused our efforts on analyses of
TCR/CD3 expression on primary T cells and on the mechanism
that might underlie the reduced expression.
In vivo removal of LAT results in reduced TCR expression
in CD4 positive T cells
Until very recently it has been difficult to determine the in vivo
function of tonic signaling and the involved signaling molecules in
peripheral T cells, because T cell development is blocked in mice
deficient for these molecules. LAT-deficient mice demonstrate an
early and severe block in thymocyte development at the CD4/
CD8 double negative stage [26], whilst RasGRP1-deficient
thymocytes arrest at the CD4/CD8 double positive stage [27].
Both the Malissen and some of us recently constructed mouse
models of inducible LAT deletion [28,29]. We exploited our novel
mouse model to examine the effects of LAT deletion in T cells on
TCR expression utilizing induced in vivo LAT deletion via
administration of tamoxifen (Figure 2C). Tamoxifen-induced
activation of ERCre (Estrogen receptor-Cre recombinase fusion
protein) results in efficient floxing of Lat’s exons 7–11, loss of Lat
protein after 3 days and induced GFP expression [30]. Here,
ERCre
+ or ERCre
2 LAT
f/2 mice were injected intraperitoneally
with 100 ml of tamoxifen (10 mg/ml) on two consecutive days and
were then treated with tamoxifen weekly. Whereas surface TCR
expression on CD4
+ T cells was unaltered 1 week after tamoxifen
treatment, we observed a significant reduction in expression 4
weeks after treatment (Figure 2D). Note that the treatment also
resulted in a relative increase in the percentage of CD4 positive
cells. The reduction in TCRb expression was specific and not
induced by tamoxifen in ERCre-negative mice that were analyzed
as controls (Figure 2D). Based on GFP expression at 4 weeks, the
LAT and RasGRP1 Maintain TCRa Expression
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a ,90% efficiency in CD4
+ T cells (Figure 2E).
Impaired tonic Ras-ERK-CD69 signaling correlates with
loss of TCRa transcripts
Previous work demonstrated that PMA directly induces
increased TCRa and TCRb expression in T cells, that is, when
protein synthesis is blocked by cycloheximide [5]. We formerly
reported that LAT-ERK/Abl signals synergize to suppress
expression of a specific cluster of genes including the RAG genes;
RAG1 and RAG2 mRNA expression is aberrantly high in LAT-
deficient J.CaM2 cells [18]. We hypothesized that similar tonic
(DAG) signals from LAT and via RasGRP1 might function to
maintain the expression levels of the direct target genes, TCRa
and/or TCRb in the basal state.
Northern blot analyses demonstrated a marked reduction of
TCRa transcript levels when LAT or RasGRP1 are absent and a
more moderate decrease in lines without SLP-76 (J14) or Vav1
(Jvav1) (Figure 3A). Similarly, levels of TCRa mRNA were reduced
in JPRM471, JPRM477, and JPRM671 (Figure 3B). Transcript
levels of TCRb were less affected by the absence of the various
signaling molecules in the basal state (Figure 3A and B). The
specific pattern of TCRa transcript levels in the various mutant
JPRM cell lines followed the pattern of basal ERK phosphoryla-
tion; the more moderate defect in basal P-ERK in JPRM477
correlated with a more moderate reduction in TCRa mRNA levels,
while TCRa transcripts were comparable to wild type control in
the JPRM563 line, which has normal basal ERK phosphorylation
(Figure 3B and 1B).
Stable reconstitution of J.CaM2 cells with wild type LAT
resulted in substantial rescue of TCRa mRNA expression.
Restoration of RasGRP1 expression did not have the same effect
on either TCRa or TCRb expression in JPRM441 (Figure 3C). The
failure to rescue TCRa or TCRb expression was not a reflection of
one particular cell line (clone 208); two independent stable clones
(clones 240 and 247 [21]) with restored RasGRP1 expression
demonstrated the same defective pattern in TCR restoration (data
not shown). We were puzzled by the lack of restoration of TCRa
and TCRb mRNA expression in RasGRP1-reconstituted
JPRM441 cells. We wondered whether there are any Ras–
dependent signals that can restore expression. Deliberate trigger-
ing of the Ras-ERK signaling pathway in these cells via high doses
of PMA did not lead to increased expression of TCRa or TCRb
mRNA (Figure 3D). In contrast, we previously showed that PMA
triggers robust induction of TCRa expression in J.CaM2 cells [18].
Similarly, transient overexpression of RasGRP1 or oncogenic H-
RasG12V in JPRM441 cells did not restore TCRa and TCRb
mRNA or surface CD3 expression in JPRM441 cells. Only co-
transfection of both TCRa- and TCRb- expression plasmids in
these cells effectively rescued CD3 expression (Figure S3). These
results indicate that tonic signals from LAT and via RasGRP1 are
important in maintaining TCRa gene expression. However, it also
appears that, while TCRa expression was substantially repressed in
LAT-deficient J.CaM2 cells, TCRa is more irreversibly repressed
in RasGRP1-deficient JPRM441, perhaps even silenced.
In vivo deletion of LAT results in time-dependent loss of
TCRa transcripts in CD4 positive T cells
Analyses of mice with deletion of LAT or expression of mutant
LAT
Y136F in peripheral T cells revealed surprising findings; these
mice developed the same lymphoproliferative disorder as when
LAT
Y136F was introduced in the germline, resulting in thymocytes
(and T cells) expressing LAT
Y136F protein [28,30,31,32]. Thus,
LAT possesses an unexpected control function in peripheral T
cells in addition to its function during thymocyte selection [33]. As
a result of loss of this control, LAT-deleted CD4
+ T cells become
CD44
+CD62L
lo by 3–4 weeks, a phenotype of activated/memory
T cells and these CD4
+ T cells produce high levels of intracellular
IL-4 [30]. We hypothesized that part of this control function
through LAT might reflect maintaining correct gene expression in
resting peripheral CD4 T cells and that loss of LAT might lead to
loss of TCRa mRNA expression, similar to what we observed in
the LAT-deficient J.CaM2 line (Figure 3).
To test this hypothesis we isolated RNA from MACS-purified
CD4
+ T cells with low levels of CD44 expression (CD44
low) that
were depleted from LAT expression for either 1 week or for 4
weeks. Taqman PCR analyses on two individual mice 1 week after
tamoxifen treatment revealed that TCRa and TCRb expression
levels were unaltered and comparable to the ERCre-negative
control (Figure 4A). However, when LAT was deleted for 4 weeks,
Figure 1. Loss of Basal Ras-ERK signaling in Jurkat-PMA-Response-Mutant (JPRM) clones. (A) RT-PCR analysis for RasGRP-1, -2, -3, -4, and
GAPDH gene expression in wild type Jurkat T cells and a panel of mutant JPRM cell lines. Five-fold dilutions of cDNA input were used as template. (B)
Western blot analysis of basal levels of phosphorylated ERK-1 and –2 in resting wild type Jurkat T cells, RasGRP1-deficient JPRM441 cells, LAT-deficient
J.CaM2 cells, and 4 additional JPRM mutant cell lines. Equal loading is indicated by a-tubulin levels on the same blot. Relative levels of ERK-1 and –2
phosphorylation were calculated by normalizing for a-tubulin and set to 100% in the Jurkat sample. (C) Western blot analysis of RasGRP1 and LAT
expression and basal levels of phosphorylated ERK-1 and –2 in the indicated resting cell types. All panels in figure 1 are representative examples of
three independent experiments.
doi:10.1371/journal.pone.0025540.g001
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+CD44
lo T cells exhibited decreased amounts transcripts of
TCRa, but preservation of TCRb (Figure 4B). Thus, TCRa mRNA
is maintained in a LAT-dependent manner in both Jurkat T cells
as well as in naı ¨ve primary CD4
+CD44
lo T cells. Loss of LAT does
not lead to an immediate reduction of TCRa transcript levels but,
rather, appears to take several weeks.
Tonic DAG-RasGRP1 signals maintain TCRa, and TCRb
transcripts.
Currently there are no mouse models available to delete
Rasgrp1 in primary T cells in an inducible manner. We therefore
took alternative approaches to substantiate a potential role of
RasGRP in tonic signaling leading to regulation of TCRa and
Figure 2. Decreased surface TCR/CD3 expression in Jurkat signaling mutant lines and primary T cells deleted for Lat. (A) Overview of
the clonal cell lines used in this study, their identified deficiencies, and surface TCR/CD3 expression characteristics. (B) Surface CD3 expressionb y
FACS analysis in the indicated cell lines. Solid grey histograms represent CD3 expression in wild type Jurkat cells. A representative example of three
independent experiments. (C) Schematic of targeting approach that allows tamoxifen-inducible excision of exons 7–11 in Lat. (D, E) Dot plot FACS
analyses of surface TCR expression levels and GFP expression against surface CD4 expression on the x-axis. Depicted are representative results of
three independent experiments obtained with lymph node cells from ERCre
2 Lat
f/2 and ERCre
+ Lat
f/2 mice that either received no tamoxifen or
tamoxifen on the first two days and subsequently every week. T cells were analyzed at 1 week or 4 weeks after the initial tamoxifen dose. Figures 2D
and 2E are representative of findings with at least three individual mice per genotype.
doi:10.1371/journal.pone.0025540.g002
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transcript levels of TCRa and TCRb in a panel of resting wild type and mutant Jurkat cell lines. Beta-actin mRNA levels were assessed as a control for
loading. (C) Northern blot analysis of transcript levels of the TCRa, TCRb, and Beta-actin in Jurkat, JPRM441, J.CaM2, and the two mutant lines stably
reconstituted with RasGRP1 or LAT cDNA. (D) Western blot analysis of Jurkat and JPRM441 samples stimulated for 10 minutes with the indicated
doses of PMA. Levels of ERK-1 and –2 phosphorylation and a-tubulin were determined on the same blot. Northern blot analysis of transcript levels of
TCRa and TCRb in wild type Jurkat and RasGRP1 deficient JPRM441 left unstimulated or stimulated with 2, 10, and 15, or for JPRM441 with 5, 15, and
25 ng/ml PMA for 20 hours, respectively. Percentages of relative expression were determined by normalizing for Beta-actin expression. The
unstimulated Jurkat sample was set at 100%. All panels in figure 3 are representative examples of three independent experiments.
doi:10.1371/journal.pone.0025540.g003
Figure 4. LAT-deletion in primary CD4
+ T cells results in time-dependent loss of TCRa transcripts. (A, B) Taqman PCR analysis of TCRa and
TCRb mRNA expression levels in sorted CD4
+CD44
low T cells from two ERCre
+ Lat
f/2 mice and one control ERCre
2 Lat
f/2 mouse. Error bars represent
taqman triplicates. The results are a representative example of two independent experiments.
doi:10.1371/journal.pone.0025540.g004
LAT and RasGRP1 Maintain TCRa Expression
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Diacylglycerol kinases (DGK) convert DAG to phosphatidic acid
and thereby limit DAG-dependent downstream signals [34]. Both
DGKf overexpression or introduction of a RasGRP1 RNAi
construct, resulted in a small, but reproducible, reduction in
surface CD3 expression that required several days to have an effect
(Figure 5A). RasGRP1 RNAi also resulted in a modest reduction
of TCRa and TCRb mRNA when RasGRP1 expression was
suppressed for 4 days (Figure 5B). No effects were observed with
shorter periods of RasGRP1 reduction (data not shown). While
modest, these effects were remarkable given the fact that the
results in Figure 5A are dependent on protein turnover, whereas in
Figure 5B only a portion of the population of wild type Jurkat cells
are transfected with the RNAi construct (,40% transfected, data
not shown).
These cell line approaches support the role of basal DAG-
RasGRP1 signals regulating surface CD3 levels and TCRa and
TCRb mRNA expression in Jurkat cells. The results also suggest
that the decrease of TCRa and TCRb mRNA expression is a
consequence of limiting DAG-RasGRP1 signals and do not occur
immediately. We previously demonstrated that tonic signals
repress RAG1 gene expression in thymocytes and that blockade
of this signal for a relatively short 24 hr.-period via addition of the
Src kinase inhibitor PP2, the Abl kinase inhibitor Gleevec or the
MEK kinase inhibitor U-0126 resulted in increased RAG1 gene re-
expression in cultured thymocytes [18]. Here we utilized the same
inhibitors to test the effects of short-term inhibition of tonic signals
on the expression levels of TCRa and TCRb in primary T cells. We
purified CD4
+CD44
lo T cells from lymph node and cultured them
without stimuli for 24 hours in vitro in the presence of these
inhibitors or DMSO as vehicle-control. Taqman PCR analyses
revealed that levels of TCRa and TCRb transcripts remained
relatively constant and were unaffected by 24-hr inhibition of the
Src-, Abl-, or MEK- kinases (Figure 5C).
The fact that changes in TCRa transcripts as a function of loss of
tonic signaling in cell lines and primary T cells took a certain
period of time to manifest (Figures 4 and 5) and the fact that TCRa
and TCRb expression was not rescued by reconstituted RasGRP1
Figure 5. Repression of TCRa expression by limiting DAG-RasGRP1 signals requires several days and can be reversed by TSA or 5-
aza inhibitors. (A) Bargraph representing mean fluorescence signals for surface expression of CD3 on wild type Jurkat cells transfected with vector
control, RasGRP1 RNAi, or DGKf expression constructs, all together with a CD16 expression construct as marker. Surface CD3 expression was
determined on CD16 positive cells, at 1, 2, or 3 days following transfection. Expression of CD3 on unmanipulated cells was arbitrarily set at 100%.
Means and standard errors of 3 independent experiments are depicted. Western blot analysis of a representative experiment, analyzing unsorted cells
for the indicated protein expression 3 days after transfection, indicates the level of FLAG-tagged DGKf expression and the degree of RasGRP1
knockdown. (B) Northern blot analysis of transcript levels of the indicated TCR components and Western blot analyses of the indicated protein
expression levels examining Jurkat T cells 4 days after transient transfection with the indicated RNAi or control construct. (C) Taqman PCR analysis of
TCRa and TCRb mRNA expression levels in sorted CD4
+CD44
low T cells from wild type mice treated for 24 hours with the indicated inhibitors in the
absence of stimuli. Error bars represent taqman triplicates. (D) Northern blot analysis of transcript levels of the indicated TCR components and
Western blot analyses of the indicated protein expression levels examining the indicated cell lines treated for 20 hours with Trichostatin A (TSA) or 5-
azacytidine (5-aza). Of note, combined treatment of TSA and 5-aza was too toxic to obtain good quality RNA. Panels 5B–5C are representative
examples of three independent experiments.
doi:10.1371/journal.pone.0025540.g005
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silencing of TCR transcripts in JPRM cells could be involved.
Hallmarks of silent chromatin are unacetylated histone proteins
and a high frequency of methylated CpG dinucleotides [35].
Histone acetyl groups can be removed by HDACs [36].
Trichostatin A (TSA) is a compound that inhibits class I and II
HDACs [37]. Methylation of CpG occurs via DNA methyltrans-
ferases (DNMTs) while demethylation occurs during DNA
replication [36]. As a consequence, de novo methylation during
DNA replication can be blocked by addition of 5-aza-29deoxycy-
tidine (5-aza). Treatment of JPRM441 with TSA resulted in re-
expression of TCRa mRNA and a more modest increase in TCRb
expression (Figure 5D). Restoration of TCRa expression was more
evident in J.CaM2 cells and TSA also induced increased levels of
TCRb transcripts in these cells. Addition of 5-aza resulted in a
similar pattern of re-expression with more moderate effects. Of
note, increased expression of TCRa and TCRb induced by TSA or
5-aza was not a result of rescue of RasGRP1 or LAT protein
expression (Figure 5D).
Discussion
Here we have demonstrated that basal LAT-DAG-RasGRP1
signals function to maintain TCRa gene expression in Jurkat T cell
lines and in a mouse model of inducible-Lat deletion. RasGRP1 is
positioned downstream of LAT in the traditional signaling cascade
that is induced when the TCR is fully stimulated by peptide-MHC
[1]. Unexpectedly, expression of TCRa mRNA in the basal state is
more strongly repressed in RasGRP1-deficient JPRM441 cells
than in LAT-deficient J.CaM2 cells. Also, TCRb expression levels
are reduced in RasGRP1-deficient Jurkat cells and in Jurkat cells
with RNAi-driven reduction of RasGRP1 expression for 4 days,
but not in LAT-deficient Jurkat cells (permanently in J.CaM2) or
in primary T cells without Lat (for 4 weeks). It appears that these
loci are less repressed and still partially accessible for transcription
factor regulation in J.CaM2 cells, i.e. so that restoration of LAT
expression or stimulation with PMA leads to re-expression of
TCRa, whereas in JPRM441 cells this did not occur. In agreement,
TSA- and 5-aza treatments had a more dramatic effect on TCRa
re-expression in J.CaM2 cells. What explains the discordant TCR
chain expression pattern in these two signaling defective cell lines
and in primary T cells? It is possible that there are additional
defective molecules in JPRM441 cell line associated with the
random EMS mutagenesis that affect expression of TCRa and
TCRb in the basal state. An additional explanation for the
difference between JPRM441 and J.CaM2 cells is that there are
functional differences between the lost basal Ras-ERK signals
when RasGRP1 or LAT is absent. Lack of the required mouse
model for inducible Rasgrp1 deletion and lack of capability to
culture viable, primary T cells for long periods of time with
inhibitors prevent us from addressing the difference between
Rasgrp1 and Lat in primary T cells at this point.
Expression of RasGRP1 or an active allele of Ras (H-RasG12V)
did not result in rescue of TCR expression. However, reconsti-
tution of JPRM441 cells with RasGRP1 did result in restoration of
PMA-induced CD69 expression [21] and expression of H-
RasG12V in JPRM441 cells results in CD69 induction as well.
Thus, while all three genes (TCRa, TCRb, and CD69) are PMA-
responsive [5,6], mechanisms of gene regulation in the basal state
appear distinct between CD69 and the TCRa and TCRb genes. In
concurrence, CD69’s chromatin appears equally accessible in
thymocytes expressing either low or high levels of surface CD69
[38]. In addition, even though both TCRa and TCRb genes are
PMA-responsive, tonic LAT-DAG-RasGRP1 signals seem to play
a more important role in the regulation of TCRa expression in the
basal state.
Various mouse models carrying hypomorphic alleles of
signaling molecules in the germline demonstrate interesting
immune phenotypes. For instance, an SKG allele of ZAP-70 with
reduced binding-affinity for phospho-TCRf leads to autoimmune
arthritis in mice [39]. As discussed, germline mutation of the single
tyrosine in LAT (LAT
Y136F) also results in an autoimmune
phenotype, accompanied with hyperproliferative lymphocytes of a
TH2 type, producing IL-4 cytokine [31,32]. It has been suggested
that these immune phenotypes are caused by altered thymocyte
selection: selection of TCR’s that display a high affinity for self
might be a way of compensation for the impaired intracellular
signaling molecules. These T cells bearing self-reactive TCRs
often lead to autoimmune syndromes in mouse models. Results
obtained with recent mouse models of inducible LAT deletion
[28,29] suggest that additional regulatory mechanisms that
operate in peripheral T cells play a role as well. Unexpectedly,
induced deletion of LAT or expression of LAT
Y136F in peripheral
T cells leads to the same lymphoproliferative syndrome as when
LAT is mutated in thymocytes [28,30,31,32]. These findings
challenge the current dogma that these autoimmune phenotypes
are exclusively caused by an altered T cell repertoire. Instead, it
appears that (tonic signals through) LAT possesses an unexpected
surveillance function in peripheral T cells [33]. We observed that
inducible removal of Lat leads to reduced TCRa mRNA
expression levels and loss of TCR surface expression on roughly
40% of the CD4 T cells within 4 weeks. We postulate that this will
lead to a further loss of constitutive TCR signals. E.g., loss of
optimal surface TCR expression may lead to less tonic signal
coming from self-MHC/TCR interactions [7], resulting in lower
basal levels of the normally observed TCRf phosphorylation [8]
and basal association of ZAP-70 with phospho-TCRf [9,10]. The
results presented here offer a potential hypothesis for the
mechanism underlying the interesting immune phenotypes
observed in mice with inducible Lat deletion [28,29] that can be
explored in the future. We postulate that tonic signals in peripheral
T cells through LAT contribute to epigenetic regulation of TCRa
transcripts and possibly other gene expression profiles and, as
such, fulfills a controlling function of T cell activity in the basal
state.
Materials and Methods
Cell lines, cell purification, stimulations, inhibitors, FACS
analysis, transfections, and RNAi
Jurkat T cells, derived JPRM, J.CaM2. J14, and JVav1 mutant
lines were grown and analyzed for expression of cell surface
markers by FACS as described before [18,21]. Surface expression
of TCR was determined using an anti TCRa/b antibody (Caltag,
MHAB01). Purification of CD4 T cells was performed by negative
depletion and MACS (magnetic cell sorting) as described before
[40]. In short, single cell suspensions were obtained, filtered, and
stained with a cocktail of biotinylated antibodies against CD117,
Ly6G, MHC class II, CD19, CD24, CD8. Cells were washed and
incubated with Streptavidin beads (Miltenyi Biotec) and run over a
depletion column avoiding saturation of the column. Cells were
seeded at 1 million/ml in RPMI supplemented with 15% fetal calf
serum. Details of stimulations, inhibitors, transfections, FACS
analysis, and RasGRP1 RNAi were previously described [18,21].
TSA was added at 20 nM, 5-aza at 2.5 mM. CD4
+ T cells from
ERCre
+ or ERCre
2 LAT
f/2 mice treated with tamoxifen were
purified by using EasySep mouse CD4+ T cell Pre-Enrichment kit
(Stemcell). The resulting cells demonstrated a 95%, 94%, and 96%
LAT and RasGRP1 Maintain TCRa Expression
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animal work has been conducted according to relevant national
and international guidelines, described in our animal protocol
‘‘Ras Signal Transduction in Lymphocytes and Cancer’’, which
was approved by the INSTITUTIONAL ANIMAL CARE AND
USE COMMITTEE (IACUC) at UCSF University California
San Francisco, protocol number AN084051-01A. Additional
animal work was performed at Duke University and procedures
were approved by the Duke University IACUC. The protocol
number for this study is A216-08-08.
Generation of EMS mutants
Jurkat PMA Response Mutants (JPRM) were generated by
mutagenesis of 100610
6 Jurkat E6-1-clone1 cells with 200 mg/ml
EMS (Sigma) for 24 hr., and subsequent selection based on a
defect in PMA-induced CD69 expression as described [21].
Plasmids
RasGRP1, H-RasG12V, PKCh(AE), CD16/7, and GFP
expression constructs were described before [21,41]. Expression
constructs for TCRa and TCRb were previously described
[42,43]. Expression of these cDNAs is driven by a constitutive
EF1-a promoter. An expression plasmid for DGKf was generously
provided by Gary Koretzky [44].
Western blot analysis
Expression levels of various proteins were determined and
quantitated by Western blot analysis of 1% NP40 lysates and
analyzed by quantitative luminescence on a Kodak Image Station
as described before [21]. Antibodies to phospho-ERK, a-tubulin,
RasGRP1, Grb-2, FLAG, Ras, and ERK proteins were previously
described [18,21]. Antibodies to LAT (Abcam) were purchased.
RNA isolation, Northern blot analysis, RT PCR, and
Taqman
RNA was isolated and TCRa and beta-actin Northern blot
hybridizations were carried out and quantified as described in detail
before [18]. For TCRb expression analysis, a 350 bp BglII-StuI
fragment was used. For RT-PCRs, first strand cDNA was produced
and RasGRP1-specific, RasGRP2-specific, RasGRP3-specific,
RasGRP4-specific, and HPRT-specific PCRs were carried out, all
as described before [21]. For TaqMan Real-Time PCR, RNA was
isolated using Trizol Reagent (Invitrogen, Carlsbad, CA) and
Chloroform (Sigma-Aldrich, St, Louis, MO) extraction followed by
RneasyMiniEluteCleanup Kit (Qiagen, Gaitherburg, MD)following
manufactures recommendations. 2 mg of RNA was converted to
cDNA by using SuperScript First-Strand Synthesis System for RT-
PCR (Invitrogen, Carlsbad, CA) following manufactures recommen-
dations for random primer procedure. TaqMan Real-Time PCRwas
done using SensiMix II Probe Kit (Bioline, Tauton, MA) following
manufacture’s recommendations. T-cell receptor alpha (Tcra), and
T-cell receptor beta (Tcrb) mRNA was expressed relative to b-actin
(Actb) using the 2
2DCT method. The Mastercycler ep realplex
2
system (Eppendorf, Hauppauge, NY) was used for all TaqMan assays
following manufactures recommendations. N=3 for all assays.
Primer and probe sequences are as follows. TCRa F59-CAAGCTT-
CACCTGCCAAGAT-39,R5 9-AAATCCGGCTACTTTCAG-
CA-39,P r o b e5 9-CGTTCCCTGTGATGCCACGTTG-39.T C R b,
F5 9-GCACAATCCTCGAAACCACT-39,R5 9-CCCTGATGA-
TAGGATGCTGAA-39, Probe 59-GTGGCCAGAGGGCTCAC-
CCA-39. bActin Mm01205647_g1 (Applied Biosystems, Foster City,
CA).
Supporting Information
Figure S1 Generation and analysis of JPRM mutant
Jurkat clones. (S1A) Screening strategy to obtain 125 mutant
Jurkat clones defective in PMA-induced CD69 upregulation. EMS
(methanesulfonic acid ethyl ester) was used to introduce random
point mutations into the Jurkat genome. Jurkat T cells are haplo-
insufficient for many genes making it possible to generate a
functional mutant line by targeting only one allele. (S1B) FACS
analysis of CD69 expression on PMA-stimulated wildtype Jurkat T
cells compared to PMA-stimulated pools of mutant cells of
subsequent rounds of negative selection. (S1C) 23 clonal lines of
the JPRM441 RasGRP1-deficient JPRM cell type belonged to a
larger selection of a total of 45 lines, all with severe defects in CD69
upregulation. FACS analysis comparing CD69 expression on
unstimulated and 20 hrs.-PMA stimulated wildtype Jurkat cells
and the indicated, clonal, mutant JPRM cell lines. (S1D) Typical
representation of a complementation assay using polyethylene
glycol (PEG)-induced cell fusion. The indicated cell lines in three
columns and three rows were individually labeled with either CFSE
or PHK26. Cells were fused making all CFSE (green) to PHK26
(red) combinations of eachcell line to itselfor to a differentline. 8 hr
later, the resultant cell populations were stimulated with PMA.
FACS dot plots demonstrate the CFSE+PHK25+ cells that were
analyzed for induced CD69 expression on the right, 16 hr after
stimulation. (S1E) FACS analysis of GFP and induced CD69
expression on Jurkat, JPRM441, JPRM471, JPRM477, JPRM563,
and JPRM671 cells, 40 hr after cotransfection of 10 mg GFP with
10 mg vector or 10 mg active H-RasG12V. Numbers indicate the
percentages of live cells in each quadrant. Similar patterns were
obtained 20 hrs. after transfection.
(JPG)
Figure S2 Survey of cell surface marker expression in
RasGRP1- and LAT-reconstituted JPRM441 and J.CaM2
mutant lines. FACS analysis of surface markers on JPRM441
and J.CaM2 mutant lines. Note that expression of CD3 and TCR
was restored to some extend in LAT reconstituted J.CaM2 cells
(J.CaM2-wtLAT) but not rescued in JPRM441-wtRasGRP1. In
contrast, CD38 expression is restored in both reconstituted lines.
CD2 and CD62L are expressed at lower levels in JPRM441 and
J.CaM2 and are not restored in either JPRM441-wtRasGRP1 or
J.CaM2-wtLAT lines. Of note, we have subcloned both the
J.CaM2 and the J.CaM2-wtLAT line through limiting dilution on
several occasions. In all subclones of J.CaM2 we consistently
detect a small shoulder of higher CD3- or TCR-expression, but
never the uniform levels of increased CD3 and TCR expression
we observe for J.CaM2-wtLAT.
(JPG)
Figure S3 Impaired CD3 expression on RasGRP1-
deficent JPRM441 is only restored upon plasmid-derived
expression of TCRa and TCRb. FACS analysis of GFP and
induced CD3 expression on JPRM441 cells, 40 hr after cotrans-
fection of 10 mg GFP with either 10 mg vector, 10 mg active H-
RasG12V, 10 mg RasGRP1 (on two different vector backbones),
10 mg TCRa,o r1 0mg TCRa+10 mg TCRb expression plasmids.
Numbers indicate the percentages of live cells in each quadrant.
(JPG)
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